Fatty Liver Disease Drug Approval Opens New Patient Population In Imaging Market

The accelerated approval of Rezdiffra, the first drug authorized by the FDA to treat metabolic dysfunction-associated steatohepatitis (MASH), presents a large opportunity for imaging and diagnostic devices.